# Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

> **NCT04260022** · PHASE1 · RECRUITING · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 242 (estimated)

## Conditions studied

- Leukemia, Myeloid, Chronic
- Myeloid Leukemia
- Chronic Myeloid Leukemia
- Philadelphia Positive Acute Lymphoblastic Leukemia
- B Cell Precursor Type Acute Leukemia

## Interventions

- **DRUG:** Ascentage Pharma HQP1351 bioavailable inhibitor
- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT04260022
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-01-09
- **Primary completion:** 2029-12-27
- **Final completion:** 2030-03-31
- **Target enrollment:** 242 (ESTIMATED)
- **Last updated:** 2025-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04260022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04260022, "Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04260022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*